Kala Pharmaceuticals (KALA) Misses Q3 EPS by 126c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts KALA Hot Sheet
Join SI Premium – FREE
Kala Pharmaceuticals (NASDAQ: KALA) reported Q3 EPS of ($3.41), $1.26 worse than the analyst estimate of ($2.15).
For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Some Said Inflation Risks Had Become More Skewed To Upside - FOMC Minutes
- Profound Medical raises Q3 2026 revenue outlook above estimates
- Jefferies Reiterates Buy Rating on Arcutis Biotherapeutics Inc. (ARQT) ahead of earnings
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
